APO Research
Talk to an analyst

APO RESEARCH · REPORT

Injectable HIV Medication

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Injectable HIV Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025178 pages

Choose your research edition.

Industry ResearchInjectable HIV Medication Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Injectable HIV Medication Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Injectable HIV Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Injectable HIV Medication Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Injectable HIV Medication Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Injectable HIV Medication market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Injectable HIV Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Injectable HIV Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Injectable HIV Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Injectable HIV Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Injectable HIV Medication include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Injectable HIV Medication market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Injectable HIV Medication and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Injectable HIV Medication sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Injectable HIV Medication market size, projected growth trends, production technologies, key applications, and end-use industries.

Injectable HIV Medication Segment by Company

Theratechnologies

ViiV Healthcare

Gilead Sciences

Janssen Pharmaceuticals

Injectable HIV Medication Segment by Type

Integrase Inhibitors

Capsid Inhibitors

NNRTIs

Monoclonal Antibodies

Other

Injectable HIV Medication Segment by Application

Pre-Exposure Prophylaxis

HIV Treatment

Injectable HIV Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable HIV Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Injectable HIV Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable HIV Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Injectable HIV Medication market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Injectable HIV Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Injectable HIV Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Injectable HIV Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Injectable HIV Medication Industry Trends Table 2. Injectable HIV Medication Industry Drivers Table 3. Injectable HIV Medication Industry Opportunities and Challenges Table 4. Injectable HIV Medication Industry Restraints Table 5. Global Injectable HIV Medication Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Injectable HIV Medication Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Injectable HIV Medication Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Injectable HIV Medication Sales Market Share by Manufacturers Table 9. Global Injectable HIV Medication Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Injectable HIV Medication Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Injectable HIV Medication Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Injectable HIV Medication Manufacturers, Product Type & Application Table 13. Global Injectable HIV Medication Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Injectable HIV Medication by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Integrase Inhibitors Table 17. Major Manufacturers of Capsid Inhibitors Table 18. Major Manufacturers of NNRTIs Table 19. Major Manufacturers of Monoclonal Antibodies Table 20. Major Manufacturers of Other Table 21. Global Injectable HIV Medication Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Injectable HIV Medication Sales by Type (2021-2026) & (K Units) Table 23. Global Injectable HIV Medication Sales by Type (2027-2032) & (K Units) Table 24. Global Injectable HIV Medication Sales Market Share by Type (2021-2026) Table 25. Global Injectable HIV Medication Sales Market Share by Type (2027-2032) Table 26. Global Injectable HIV Medication Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Injectable HIV Medication Revenue by Type (2021-2026) & (K Units) Table 28. Global Injectable HIV Medication Revenue by Type (2027-2032) & (K Units) Table 29. Global Injectable HIV Medication Revenue Market Share by Type (2021-2026) Table 30. Global Injectable HIV Medication Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Pre-Exposure Prophylaxis Table 32. Major Manufacturers of HIV Treatment Table 33. Global Injectable HIV Medication Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Injectable HIV Medication Sales by Application (2021-2026) & (K Units) Table 35. Global Injectable HIV Medication Sales by Application (2027-2032) & (K Units) Table 36. Global Injectable HIV Medication Sales Market Share by Application (2021-2026) Table 37. Global Injectable HIV Medication Sales Market Share by Application (2027-2032) Table 38. Global Injectable HIV Medication Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Injectable HIV Medication Revenue by Application (2021-2026) & (K Units) Table 40. Global Injectable HIV Medication Revenue by Application (2027-2032) & (K Units) Table 41. Global Injectable HIV Medication Revenue Market Share by Application (2021-2026) Table 42. Global Injectable HIV Medication Revenue Market Share by Application (2027-2032) Table 43. Global Injectable HIV Medication Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Injectable HIV Medication Sales by Region (2021-2026) & (K Units) Table 45. Global Injectable HIV Medication Sales Market Share by Region (2021-2026) Table 46. Global Injectable HIV Medication Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Injectable HIV Medication Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Injectable HIV Medication Sales by Country (2021-2026) & (K Units) Table 50. North America Injectable HIV Medication Sales by Country (2027-2032) & (K Units) Table 51. Europe Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Injectable HIV Medication Sales by Country (2021-2026) & (K Units) Table 53. Europe Injectable HIV Medication Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Injectable HIV Medication Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Injectable HIV Medication Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Injectable HIV Medication Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Injectable HIV Medication Sales by Country (2027-2032) & (K Units) Table 60. Global Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Injectable HIV Medication Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Injectable HIV Medication Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Injectable HIV Medication Revenue Market Share by Region (2021-2026) Table 64. Global Injectable HIV Medication Revenue Market Share by Region (2027-2032) Table 65. Theratechnologies Company Information Table 66. Theratechnologies Business Overview Table 67. Theratechnologies Injectable HIV Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Theratechnologies Injectable HIV Medication Product Portfolio Table 69. Theratechnologies Recent Development Table 70. ViiV Healthcare Company Information Table 71. ViiV Healthcare Business Overview Table 72. ViiV Healthcare Injectable HIV Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. ViiV Healthcare Injectable HIV Medication Product Portfolio Table 74. ViiV Healthcare Recent Development Table 75. Gilead Sciences Company Information Table 76. Gilead Sciences Business Overview Table 77. Gilead Sciences Injectable HIV Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Gilead Sciences Injectable HIV Medication Product Portfolio Table 79. Gilead Sciences Recent Development Table 80. Janssen Pharmaceuticals Company Information Table 81. Janssen Pharmaceuticals Business Overview Table 82. Janssen Pharmaceuticals Injectable HIV Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Janssen Pharmaceuticals Injectable HIV Medication Product Portfolio Table 84. Janssen Pharmaceuticals Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Injectable HIV Medication Distributors List Table 88. Injectable HIV Medication Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Injectable HIV Medication Product Image Figure 2. Global Injectable HIV Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Injectable HIV Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global Injectable HIV Medication Sales (2021-2032) & (K Units) Figure 5. Global Injectable HIV Medication Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Injectable HIV Medication Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Integrase Inhibitors Image Figure 9. Capsid Inhibitors Image Figure 10. NNRTIs Image Figure 11. Monoclonal Antibodies Image Figure 12. Other Image Figure 13. Global Injectable HIV Medication Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Injectable HIV Medication Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Injectable HIV Medication Sales Market Share by Type (2021-2032) Figure 16. Global Injectable HIV Medication Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Injectable HIV Medication Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Injectable HIV Medication Revenue Market Share by Type (2021-2032) Figure 19. Pre-Exposure Prophylaxis Image Figure 20. HIV Treatment Image Figure 21. Global Injectable HIV Medication Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Injectable HIV Medication Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Injectable HIV Medication Sales Market Share by Application (2021-2032) Figure 24. Global Injectable HIV Medication Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Injectable HIV Medication Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Injectable HIV Medication Revenue Market Share by Application (2021-2032) Figure 27. North America Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Injectable HIV Medication Sales Market Share by Country (2021-2032) Figure 29. U.S. Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Injectable HIV Medication Sales Market Share by Country (2021-2032) Figure 34. Germany Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Injectable HIV Medication Sales Market Share by Country (2021-2032) Figure 41. China Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Injectable HIV Medication Sales Market Share by Country (2021-2032) Figure 49. Brazil Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Injectable HIV Medication Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Injectable HIV Medication Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Injectable HIV Medication Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Injectable HIV Medication Revenue (2021-2032) & (US$ Million) Figure 60. North America Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Injectable HIV Medication Revenue (2021-2032) & (US$ Million) Figure 62. Europe Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Injectable HIV Medication Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Injectable HIV Medication Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Injectable HIV Medication Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Injectable HIV Medication Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Integrase Inhibitors
  • Capsid Inhibitors
  • NNRTIs
  • Monoclonal Antibodies
  • Other
Applications
  • Pre-Exposure Prophylaxis
  • HIV Treatment
Companies covered
  • Theratechnologies
  • ViiV Healthcare
  • Gilead Sciences
  • Janssen Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Injectable HIV Medication Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Injectable HIV Medication Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Injectable HIV Medication Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Injectable HIV Medication Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Injectable HIV Medication Market Dynamics
  1. 2.1 Injectable HIV Medication Industry Trends
  2. 2.2 Injectable HIV Medication Industry Drivers
  3. 2.3 Injectable HIV Medication Industry Opportunities and Challenges
  4. 2.4 Injectable HIV Medication Industry Restraints
3 Injectable HIV Medication Market by Manufacturers
  1. 3.1 Global Injectable HIV Medication Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Injectable HIV Medication Sales by Manufacturers (2021-2026)
  3. 3.3 Global Injectable HIV Medication Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Injectable HIV Medication Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Injectable HIV Medication Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Injectable HIV Medication Manufacturers, Product Type & Application
  7. 3.7 Global Injectable HIV Medication Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Injectable HIV Medication Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Injectable HIV Medication Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Injectable HIV Medication Tier 1, Tier 2, and Tier 3
4 Injectable HIV Medication Market by Type
  1. 4.1 Injectable HIV Medication Type Introduction
  2. 4.1.1 Integrase Inhibitors
  3. 4.1.2 Capsid Inhibitors
  4. 4.1.3 NNRTIs
  5. 4.1.4 Monoclonal Antibodies
  6. 4.1.5 Other
  7. 4.2 Global Injectable HIV Medication Sales by Type
  8. 4.2.1 Global Injectable HIV Medication Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Injectable HIV Medication Sales by Type (2021-2032)
  10. 4.2.3 Global Injectable HIV Medication Sales Market Share by Type (2021-2032)
  11. 4.3 Global Injectable HIV Medication Revenue by Type
  12. 4.3.1 Global Injectable HIV Medication Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Injectable HIV Medication Revenue by Type (2021-2032)
  14. 4.3.3 Global Injectable HIV Medication Revenue Market Share by Type (2021-2032)
5 Injectable HIV Medication Market by Application
  1. 5.1 Injectable HIV Medication Application Introduction
  2. 5.1.1 Pre-Exposure Prophylaxis
  3. 5.1.2 HIV Treatment
  4. 5.2 Global Injectable HIV Medication Sales by Application
  5. 5.2.1 Global Injectable HIV Medication Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Injectable HIV Medication Sales by Application (2021-2032)
  7. 5.2.3 Global Injectable HIV Medication Sales Market Share by Application (2021-2032)
  8. 5.3 Global Injectable HIV Medication Revenue by Application
  9. 5.3.1 Global Injectable HIV Medication Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Injectable HIV Medication Revenue by Application (2021-2032)
  11. 5.3.3 Global Injectable HIV Medication Revenue Market Share by Application (2021-2032)
6 Global Injectable HIV Medication Sales by Region
  1. 6.1 Global Injectable HIV Medication Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Injectable HIV Medication Sales by Region (2021-2032)
  3. 6.2.1 Global Injectable HIV Medication Sales by Region (2021-2026)
  4. 6.2.2 Global Injectable HIV Medication Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Injectable HIV Medication Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Injectable HIV Medication Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Injectable HIV Medication Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Injectable HIV Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Injectable HIV Medication Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Injectable HIV Medication Revenue by Region
  1. 7.1 Global Injectable HIV Medication Revenue by Region
  2. 7.1.1 Global Injectable HIV Medication Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Injectable HIV Medication Revenue by Region (2021-2026)
  4. 7.1.3 Global Injectable HIV Medication Revenue by Region (2027-2032)
  5. 7.1.4 Global Injectable HIV Medication Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Injectable HIV Medication Revenue (2021-2032)
  8. 7.2.2 North America Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Injectable HIV Medication Revenue (2021-2032)
  11. 7.3.2 Europe Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Injectable HIV Medication Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Injectable HIV Medication Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Injectable HIV Medication Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Theratechnologies
  2. 8.1.1 Theratechnologies Company Information
  3. 8.1.2 Theratechnologies Business Overview
  4. 8.1.3 Theratechnologies Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Theratechnologies Injectable HIV Medication Product Portfolio
  6. 8.1.5 Theratechnologies Recent Developments
  7. 8.2 ViiV Healthcare
  8. 8.2.1 ViiV Healthcare Company Information
  9. 8.2.2 ViiV Healthcare Business Overview
  10. 8.2.3 ViiV Healthcare Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ViiV Healthcare Injectable HIV Medication Product Portfolio
  12. 8.2.5 ViiV Healthcare Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Injectable HIV Medication Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Janssen Pharmaceuticals
  20. 8.4.1 Janssen Pharmaceuticals Company Information
  21. 8.4.2 Janssen Pharmaceuticals Business Overview
  22. 8.4.3 Janssen Pharmaceuticals Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Pharmaceuticals Injectable HIV Medication Product Portfolio
  24. 8.4.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Injectable HIV Medication Value Chain Analysis
  2. 9.1.1 Injectable HIV Medication Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Injectable HIV Medication Production Mode & Process
  6. 9.2 Injectable HIV Medication Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Injectable HIV Medication Distributors
  9. 9.2.3 Injectable HIV Medication Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst